Sanofi abandons eczema drug approval efforts in another blow to OX40 class

RegulatoryrejectedamlitelimabNegative

AI Analysis

Summary

Sanofi has abandoned development of amlitelimab, an OX40 inhibitor for eczema treatment, citing concerns about the drug's value proposition relative to existing eczema therapies.

Outcome Details

Development discontinued due to concerns about differential value compared to other eczema treatments

Importance:6/10

Sentiment:

-0.80

drug_discontinuationOX40_inhibitordermatologyeczema

Related Companies

$SNY

Read the original article

Published by Pharmaceutical Technology on July 24, 2026 1:20 PM

Read Original